Dypha: adding the dimension of time to cell culture
The δypha System aims to enhance drug development by providing a plug-and-play microfluidic adaptor for 96 well plates, enabling precise control of fluid kinetics in cell culture models.
Projectdetails
Introduction
The current preclinical drug development pipeline is highly inefficient with 9 out of 10 drugs failing when first tested in humans. Of those failures, between 69% and 81% is due to a lack of efficacy (52-57%) or safety (17-24%), indicating that the predictivity of currently used cell culture and animal models is not high enough.
Limitations of Current Models
While promising human cell culture models have arisen in the last decades (e.g. pluripotent stem cell models, spheroids, organoids), the environment of these models is too simplistic to reach their full potential and to translate certain responses to humans.
Kinetics in Cell Culture
One of the important aspects missing in current cell culture is kinetics: many processes in the human body have response times with resolutions of seconds, minutes, or hours. In standard cell culture, however, such temporal resolution is absent because cell culture medium remains unchanged for typically 1-3 days.
Challenges with Animal Models
For kinetics, scientists turn to animal models with relatively low translational success and high costs.
Alternative Solutions
As an alternative, complex microfluidic setups have been used to enable perfusion in vitro and demonstrated a significant amount of evidence that kinetics can improve the relevance of cell culture models. Despite the evidence, typical cell culture biologists are not taking kinetics into account because the tools to control kinetics in cell culture are too complex.
Our Solution
We solve this problem by starting from what cell culture biologists currently use: a standard well plate. We developed a µFluidic Adaptor that can be clamped on any 96 well plate and completely replaces the fluid in the well homogenously without disturbing the cell culture.
Goals and System Overview
Our goal is to develop a plug-and-play peripheral system that integrates automated fluidics and microscopic readout in a fully controlled environment: the δypha System. The system uses µFluidic Adaptors that can be designed for different applications or well plate formats.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.499.625 |
Totale projectbegroting | € 2.499.625 |
Tijdlijn
Startdatum | 1-4-2024 |
Einddatum | 31-3-2027 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- DEMCON SYNC BIOSYSTEMS BVpenvoerder
- ESQLABS GMBH
- OSPEDALE PEDIATRICO BAMBINO GESU
- PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV
- CHARLES RIVER NEDERLAND BV
- DEMCON LIFE SCIENCES & HEALTH ENSCHEDE BV
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Prefabricated Mature Blood Vessels and Tools for Vascularized 3D Cell CultureThe Vasc-on-Demand project aims to develop three innovative products for easy generation of vascularized 3D tissues, enhancing research and drug testing while reducing reliance on animal trials. | EIC Transition | € 2.488.750 | 2024 | Details |
IDEFIX Multiorgan toxicity and efficacy test platformCherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions. | EIC Transition | € 2.496.073 | 2022 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Prefabricated Mature Blood Vessels and Tools for Vascularized 3D Cell Culture
The Vasc-on-Demand project aims to develop three innovative products for easy generation of vascularized 3D tissues, enhancing research and drug testing while reducing reliance on animal trials.
IDEFIX Multiorgan toxicity and efficacy test platform
Cherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
High-throughput combinatory drugs testing on in vitro 3D cells model platformThe project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer. | ERC Proof of... | € 150.000 | 2023 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
High Throughput Modelling and Measurement of Human Epithelial Models using Electrospun Conducting Polymers For Unlocking Data-Driven Drug DiscoveryThe project aims to enhance drug discovery by developing simplified Organ on Chip platforms through hydrogel electrospinning, enabling scalable monitoring and integration into industry workflows. | ERC Proof of... | € 150.000 | 2025 | Details |
High-throughput production of anisotropic 3D human tissue modelsDeveloping a magnetic hydrogel system to create 3D tissue models that accurately mimic human tissue architecture, enhancing drug discovery and personalized medicine efficiency. | ERC Proof of... | € 150.000 | 2024 | Details |
Biomimetic Sensorized Barriers-on-a-Chip: Unveiling a new Generation of Market-Ready Investigation ToolsThis project aims to validate a novel, dynamic blood-brain barrier model with sensing features for improved drug screening in CNS pathologies, reducing reliance on animal testing and clinical trial failures. | ERC Proof of... | € 150.000 | 2024 | Details |
High-throughput combinatory drugs testing on in vitro 3D cells model platform
The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
High Throughput Modelling and Measurement of Human Epithelial Models using Electrospun Conducting Polymers For Unlocking Data-Driven Drug Discovery
The project aims to enhance drug discovery by developing simplified Organ on Chip platforms through hydrogel electrospinning, enabling scalable monitoring and integration into industry workflows.
High-throughput production of anisotropic 3D human tissue models
Developing a magnetic hydrogel system to create 3D tissue models that accurately mimic human tissue architecture, enhancing drug discovery and personalized medicine efficiency.
Biomimetic Sensorized Barriers-on-a-Chip: Unveiling a new Generation of Market-Ready Investigation Tools
This project aims to validate a novel, dynamic blood-brain barrier model with sensing features for improved drug screening in CNS pathologies, reducing reliance on animal testing and clinical trial failures.